The interaction between the bone marrow microenvironment and malignant hematopoietic cells can result in the protection of leukemia cells from chemotherapy in both myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). We, herein, characterized the changes in cytokine expression and the function of mesenchymal stromal cells (MSC) in patients with MDS, AML with myelodysplasiarelated changes (MRC), a well-recognized clinical subtype of secondary AML, and de novo AML. We observed a significant inhibitory effect of MDS-MSC on T lymphocyte proliferation and no significant differences in any of the cytokines tested. AML-MSC inhibited T-cell proliferation only at a very low MSC/T cell ratio. When compared to the control, AML-MRC derived MSC presented a significant increase in IL6 expression, whereas de novo AML MSC presented a significant increase in the expression levels of VEGFA, CXCL12, RPGE2, IDO, IL1β, IL6 and IL32, followed by a decrease in IL10 expression. Furthermore, data indicate that IL-32 regulates stromal cell proliferation, has a chemotactic potential and participates in stromal cell crosstalk with leukemia cells, which could result in chemoresistance. Our results suggest that the differences between AML-MRC and de novo AML also extend into the leukemic stem cell niche and that IL-32 can participate in the regulation of the bone marrow cytokine milieu.
. HSC self-renewal, differentiation and proliferation are regulated in local tissue microenvironments called niches. One of the main cellular components of the HSC niche are the mesenchymal stromal cells (MSC), which are important regulators of haematopoiesis, as well as of the immune system 4, 5 . It is rational to assume that MSC, derived from patients with hematological malignancies, harbor some partial defects, either primary or secondary, due to their exposure to altered marrow components. Extensive data have already shown interactions between leukemic cells and their microenvironment, supporting the idea that defects in the HSC microenvironment may play a role either in MDS or in AML development [6] [7] [8] [9] . For instance, interactions between MSC from the leukemic stem cell niche and malignant cells are critical components of resistance to many chemotherapy agents [10] [11] [12] .
One of the hallmarks of malignancy 13 , inflammation, has been recognized as an important factor in the pathogenesis of MDS and AML, and involves different molecular and cellular signaling pathways 1, [14] [15] [16] . Thus, the continuous inflammatory state provided by the HSC leukemic niche can contribute to the initiation and progression of diseases. Interleukin (IL)-32 is a proinflammatory cytokine, expressed as several isoforms 17, 18 , that is thought to contribute to the pathogenesis of infection [19] [20] [21] , autoimmune diseases 21 and cancer 22, 23 . IL-32
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induces inflammatory cytokines such as TNF-α , IL-1β , IL-6, and chemokines through the NF-κ B and p38 MAPK signaling pathways 17 . Previous data support a role for IL-32 in the pathophysiology of clonal myeloid diseases 24 . In this study, we characterized cytokine expression changes and the function of MSC from patients with MDS, AML-MRC and de novo AML, in comparison to healthy control (HC) MSC. Moreover, we studied the ability of IL-32 to promote cell proliferation, chemotaxis of leukocytes and chemoprotection towards cytarabine (AraC) in the microenvironment.
Results
Expansion and characterization of MSC. MSC were cultured to confluence until the fourth passage. All 8 samples obtained from HC were successfully cultured, while only 71% of the samples obtained from MDS (22 of 31), 70% from AML-MRC (7 of 10) and 71% from de novo AML (12 of 17) were able to proliferate. The mean time to reach 80% confluency of samples obtained from MDS and AML-MRC were similar to those of HC (15 ± 6.2; 12.6 ± 6.1; 13.5 ± 2.4 days, respectively, p > 0.05).
De novo AML cells reached 80% confluency in 21.2 ± 8.2 days, which represents a significantly slower growth than that of HC and AML-MRC samples (p < 0.05). Confirming mesenchymal origin, all patient-derived MSC presented a typical profile, standardized by the International Society for Cellular Therapy 25 , and very similar to that of HC-MSC (Supplementary Table 2 ). Low levels of CD34 and CD31 were sometimes detected in the AML-MRC group, either due to leukemia cell or endothelial cell contamination 26 or due to macrophage contamination 27 . To assess the capacity and efficiency for self-renewal of the MSC, a colony-forming unit-fibroblast (CFU-F) assay was performed in some of our patient-derived cells (5 samples of MDS and 2 samples of AML). The MSC derived from MDS patients showed a median of 23.2 CFU-F (range: 16-37) per 10 3 cells. The samples from MSC-derived AML presented 28 and 8 CFU-F per 10 3 cells. These results indicate the self-renewal capacity of our MSC derived from patient bone marrow.
Immunomodulative capability. The immunomodulatory properties of MSC have been well characterized 28 , including suppression of T cell-mediated immunity 29 . Herein, the ability of patient-derived MSC to inhibit T cell proliferation was analyzed by mixing different ratios of MSC and CFSE-labeled CD3 + cells, in the presence of PHA. We observed a significant inhibitory effect of MDS-MSC on CD3
+ cell proliferation up to the ratio of 1:100 (p < 0.05), in a dose-dependent manner, similar to that of HC-MSC (Fig. 1 ). This result remained significant when MDS patients were classified into subgroups, according to the WHO 2008 classification (data not shown). On the other hand, in contrast to HC-MSC, which presented normal inhibitory properties, AML-derived MSC were able to significantly inhibit T-cell proliferation at lower ratios. AML-MRC derived-MSC only inhibited proliferation at a ratio of 1:2 (p < 0.001), and the de novo AML MSC inhibited up to a ratio of 1:10 (p < 0.01) (Fig. 1) . Further studies are needed to address the key aspects of the reduction of AML-MSC-mediated immunosuppression. Cytokine profile in MSC. We next characterized the mRNA expression of cytokines and other molecules in patient-derived MSC and compared these to the HC samples. No significant difference was detected in the MDS-derived MSC group (Fig. 2) . AML-MRC-derived MSC showed a significant increase in IL6 expression (p = 0.02). However, de novo AML MSC presented a significant increase in expression levels of vascular endothelial growth factor A (VEGFA), stromal cell-derived factor 1 (CXCL12), receptor of prostaglandin E2 (RPGE2), indoleamine 2,3-dioxygenase (IDO), IL6 and IL32 (all p < 0.05), followed by a decrease in IL10 expression (p = 0.009) when compared to the HC group. We also observed a significantly increased expression of VEGFA, CXCL12, RPGE2 and IL32 in de novo AML, when compared with AML-MRC-derived MSC (p < 0.05). There were no differences in the expressions of TGFβ1 and IL1β.
We also analyzed the expression of the four best characterized isoforms of IL32 in our cohort. De novo AML MSC presented a significant increase in the expression levels of IL32γ(p = 0.01), the IL-32 isoform with the highest biological activity 30 . There were no differences in the expressions of the IL32α, β and δ transcripts (Supplemental Figure S1 ). Silencing of IL-32 by miRNA and HS5 cell proliferation. Several studies have demonstrated that IL-32 plays a role in the inflammatory microenvironment and that there is a network between IL-32 and other cytokines such as IL-1β , IL-6, IL-10 and VEGF 17, 19, 21, 22, [31] [32] [33] . To investigate the relation between IL-32 and MSC, we used HS5, a cell line with a stromal phenotype and with the ability to secret several cytokines, including IL-6 and IL-1, and to support hematopoiesis 34 . Since inflammation triggers MSC activity 35 , we also performed our experiments upon stimulation with IFN-γ and TNF-α . HS5 cells were stably transduced with two lentiviral constructs encoding miRNA targeting IL32 (miIL32#1 and miIL32#2) or with miControl. After polyclonal cell selection with blasticidin, the efficiency of IL-32 silencing was analyzed by Western blotting. A significant reduction in IL-32 protein levels was observed in both constructions of miIL32 HS5, compared with miControl cells under regular and inflammatory conditions ( Fig. 3A and B) .
IL-32 is reported to have hematopoietic growth factor properties 36 , while IL-32 silencing results in a reduction in endothelial cell proliferation 37 . To determine whether IL-32 silencing affects stromal cell proliferation and/or viability, MTT assays were performed. Unexpectedly, viability of miIL32 HS5 cells was significantly increased (by ~40%) when compared with miControl cells, with or without pro-inflammatory stimulation (p < 0.05; Fig. 3C ). Ki-67 analysis revealed that IL-32 silencing significantly increased cell proliferation (Fig. 3D ).
Chemotactic activity of IL-32 on PBMCs. Cell migration is essential for the induction of an effective immune response. To test whether IL-32 has any effect on PBMC recruitment, transwell chemotaxis of PBMC was performed in coculture with miControl or miIL32 HS5 cells. The number and type of PBMC that migrated through the membrane were analyzed. There was a significant decrease in CD45 + cells migration, which mainly reflects the significant decrease in CD4 + migration, with or without proinflammatory stimulation (p < 0.05; Fig. 4) .
Similar effects on cell function were observed after IL-32 silencing with both the miIL32 sequences, implying that these effects are the result of RNAi-mediated silencing of the IL-32 gene rather than off-target effects. Since miIL32#2 showed a slightly better efficiency, we chose to carry out the subsequent experiments with this sequence.
Chemoprotection to AraC conferred by miIL32 HS5 cells. We firstly evaluated whether IL-32 silencing could modify the chemoprotection to AraC-induced apoptosis, the most effective drug for the treatment of AML 38 , conferred by HS5 to U937 cells 39 . As observed in Fig. 5A , IL-32 silencing does not modify the resistance of U937 cells to AraC when they are in contact with HS5 (p < 0.001).
Next, we tested whether the supernatant of miIL32 HS5 cells could change the chemosensitivity of U937 cells to AraC, using a transwell system. In these conditions, we observed that HS5 cells still protect U937 from AraC cytotoxicity. However, noncontact with miIL32 HS5 was significantly more effective than the miControl in inhibiting AraC-induced apoptosis of U937 cells (p < 0.05; Fig. 5B and D) . Interestingly, this effect was reverted by the addition of TNF-α ( Fig. 5C and D) .
Modulation of cytokines, chemokines, MAPK and NF-κB signaling by IL-32. We also measured, in serum-free supernatants from cell culture of miControl and miIL32, the levels of cytokines and chemokines, in order to assess whether IL-32 regulates their expression in the stromal cell. The major cytokines downmodulated by IL-32 are demonstrated in Fig. 6A and B.
The ability of IL-32 to activate the p38 mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κ B) pathways has been previously reported 17, 40, 41 . Herein, we sought to examine the effect of IL-32 on MAPK and NF-κ B signaling in our stromal cell line model. We observed that IL-32 depletion (Fig. 6C ) resulted in a decrease in phosphorylation of NF-κ B, IKKα , IKKβ , c-Jun N-terminal kinase (JNK) and p38 MAPK (Fig. 6C and D) . + cells in an inflammatory environment. miIL32 and miControl HS5 cells were seeded in the lower chamber of transwell plates with or without the addition of IFN-γ and TNF-α for 24 h before adding PBMCs, which were allowed to migrate for 5 h. Data represent mean ± SEM (4 independent experiments). ANOVA, Bonferroni's post-tests (**p < 0.01; ***p < 0.001).
Furthermore, we analyzed the phosphorylation levels of NF-κ B in samples from patient-derived MSC and HC-derived MSC. In this small set of patient-derived cells, NF-κ B phosphorylation levels were higher in the AML-derived MSC, especially in de novo AML samples (Fig. 6E ). This finding is worthy of further research.
Discussion
In this report, we characterized and compared MSC derived from patients with MDS, AML-MRC and de novo AML with these from healthy controls. Although MSC from patients exhibited a typical antigen expression profile, as already described by others 42 , we observed a reduced immunosuppressive ability of AML-MSC when compared to the control. There are few studies about the immunosuppressive ability of AML-derived MSC 43 , although studies about MDS-MSC immunosuppressive function have been controversial [43] [44] [45] [46] . We found that MDS-MSC were capable of satisfactorily inhibiting T cell proliferation in vitro induced by PHA, even when we classified our cohort as low or high-risk MDS, according to the WHO 2008 classification 2 . Supporting this finding, we observed no significant difference in any cytokine or molecule studied in the MDS-MSC. In agreement with Klaus et al. 44 , our data suggest that MDS-derived MSC are not the main factor responsible for the aberrant T cell response, sometimes observed in MDS patients.
We also demonstrated a distinct cytokine profile between AML-MRC and de novo AML-derived MSC, suggesting that the difference between these two AML subtypes also extends into the leukemic stem cell niche. AML-MRC is characterized by the persistence of the malignancy, alterations in the hematopoietic niche caused by prior MDS treatment, a higher frequency of molecular mutations and cytogenetic abnormalities 47 . We observed that, despite the impaired immunosuppressive ability of the AML-MRC-derived MSC, their cytokine profile is very similar to that of the control group. Conversely, de novo AML-derived MSC presented a significant increase in their expressions of VEGF and IL6, both of which are secreted by the leukemic blast in order to promote their survival and proliferation [48] [49] [50] [51] . Recently, Kim et al. 52 demonstrated that leukemia stem cells from de novo AML patients can induce extensive alterations in the mesenchymal niche, resulting in an altered expression of crosstalk molecules, including CXCL12. Together with the lower IL10 expression 53, 54 , and the higher expression of IDO [55] [56] [57] , CXCL12 [58] [59] [60] and RPGE2 61-63 observed in our de novo AML cohort, we suggest that at least at the beginning of this disease, prior to any treatment, MSC provides a permissive niche for leukemogenesis rather than normal hematopoiesis. Marcondes et al. 22 showed an increase in IL32 expression in the bone marrow stromal cells from 13 patients with MDS. Nevertheless, in our cohort of 22 MDS patients we could not see any statistical difference between the MDS and HC groups. These differences may due to either a lack of standardized culture for bone marrow MSC or the heterogeneity of MDS patients. Furthermore, in de novo AML-derived MSC, we observed a significantly higher expression level of IL32, which reflects the expression of the most active isoform, IL32γ. It has been shown that the over expression of IL-32γ in an animal model resulted in the inhibition of the cell proliferation of melanoma and colon tumors 64 . Our results suggest that the higher expression of IL32γ in de novo AML-derived MSC could contribute to the slower-growing cells generated from these patients samples, as observed in our study. Accordingly, our in vitro results show that IL-32 inhibition resulted in a significantly increased stromal cell proliferation, with our without proinflammatory stimulation. IL-32 may have pleiotropic effects on cell proliferation, as indicated by many other cellular functions [65] [66] [67] [68] [69] [70] . Son et al. demonstrated that endogenously-secreted IL-32γ may regulate a variety of immune responses via CCL5 expression from dendritic cells, including chemotaxis of activated T cells 71 . We observed that silencing of IL-32 resulted in lower concentrations of CCL5 in the supernatant of HS5 cells, which may explain the significantly decreased migration of CD4 + cells when cocultured with HS5 miIL32 cells. Additionally, many other important inflammatory molecules, including VEGF, TNF-α , IFN-γ , and IL-6 were reduced in the supernatant of HS5 miIL32 cells.
Our study on AraC-mediated cytotoxicity has shown that coculture of HS5 miControl or miIL32 with U937 cells in vitro resulted in the same levels of enhanced protection compared to U937 without HS5 cells. However, the coculture of HS5 miIL32 with U937 cells using transwell assays resulted in a significant protection from AraC-induced apoptosis when compared to the coculture with HS5 miControl. It has been described that HS5 cells can secrete a soluble factor(s) that protect U937 from AraC induced apoptosis 72 . Herein, we showed that IL-32 has a role in stromal cell crosstalk with leukemia cells, and that TNF-α must be part of this network, at least in vitro, since the protection from AraC-induced apoptosis conferred by HS5 miIL32 was reversed upon the addition of TNF-α . In a recent studies, it was shown that IL-32α suppressed colon cancer development by promoting the death signaling of TNFR1 73 , and that IL-32γ can induce TFN-α production in differentiated THP1 cell line 74 . Proliferation, leukocyte chemotaxis and regulation of the apoptotic threshold depend on appropriate signals through a favorable cytokine milieu for their homing to the bone marrow [75] [76] [77] [78] . Our results suggest that IL-32 participates in the regulation of the bone marrow cytokine milieu, at least in part, through MAPK and NF-κ B signaling.
In conclusion, we have shown a distinct function and cytokine profiles in AML-MRC and de novo AML-derived MSC, including the expression of IL-32. We also demonstrate that IL-32 takes part in the chemoresistance induced by MSC.
Materials and Methods
Primary samples. For isolation and expansion of MSC, bone marrow cells were obtained from 8 healthy donors (healthy control; HC) and 22 MDS and 19 AML patients. For the T cell proliferation and chemotaxis assay, peripheral blood mononuclear cells (PBMC) from HC (n = 26) were obtained by Ficoll-Hypaque gradient separation. All HC and patients provided their informed written consent, and all experiments were performed in accordance with the ethical and care guidelines and were approved by the local ethics committee of the University of Campinas and was adherent to the Declaration of Helsinki. Patients were untreated at the time of sample collection. Patients' characteristics are described in Supplementary 
Cell lines and chemical reagents.
The human bone marrow stromal cell line, HS5, and the human acute myeloid leukemia cell line, U937 79 , were obtained from the American Type Culture Collection (Manassas, VA, USA). 293FT and HT1080 cells were acquired in 2012 from Invitrogen (Carlsbad, CA, USA). Cells were cultured in appropriated medium, according to the manufacturer's instruction, containing 10% fetal bovine serum (FBS) and glutamine with penicillin/streptomycin and amphotericin B, and maintained at 37 °C, 5% CO 2 . Recombinant human TNF-α and IFN-γ were purchased from PeproTech (Rocky Hill, NJ, USA). Cytarabine (AraC) was obtained from Intas Pharmaceuticals (Ahmedabad, India) and prepared as a 10 mM stock solution.
Isolation and expansion of MSC from bone marrow. Mononuclear cells were isolated from bone marrow by density gradient centrifugation and seeded at a density of 10 6 cells/cm 2 . After 3-4 days of adhesion, non-adherent cells were removed. Cells were cultured at 37 °C, 5% CO 2 in DMEM medium containing 1% penicillin/streptomycin, 1% L-glutamine and 10% fetal bovine serum, as described previously 80 . After achieving 80% confluence, the cells were removed with trypsin and plated again at a concentration of 4 × 10 3 cells/cm 2 , for further passages. We performed all analyses at the fourth passage.
Quantitative PCR (q-PCR). Total RNA was purified using the TRIzol Reagent (Invitrogen). The reverse transcription reaction was performed using RevertAid First Strand cDNA synthesis kit (MBI Fermentas, Amherst, NY, USA). Expression of mRNAs was detected by qPCR with the Maxima SYBR Green qPCR master mix (MBI Fermentas) using the ABI 7500 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). HPRT was used as an endogenous control (sequences of all genes at Supplementary Table 3 Fibroblastic colony-forming unit (CFU-F) assay. CFU-F assays were performed by plating 1 × 10 3 cells/ well in 6-well plates. The medium was changed on day 7. After 15 days of culture, adherent cells were washed twice with phosphate-buffered saline, and stained with 1% crystal-violet in methanol. CFU-F colonies were macroscopically enumerated and clusters of more than 50 cells were considered as colonies.
T cell proliferation assay. CD3
+ cells were purified from isolated PBMC, by magnetic separation of bead-bound cells (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Purity of CD3
+ cells was 90-95%, as assessed by flow cytometry. CFSE-labeled CD3 + cells were resuspended and added to wells (10 5 cells/well) containing MSC at MSC/T cells ratios of 1:2, 1:5, 1:10, 1:50 and 1:100 in the presence of PHA (2,5 μ g/mL). Four days later the CFSE fluorescence intensity was analyzed by flow cytometry (Becton-Dickinson).
Preparation of lentiviral vectors. Lentiviral vectors, expressing microRNA (miRNA) and targeting human IL-32 or LacZ were prepared using the BLOCK-iT Pol II miR RNAi Expression Vector with EmGFP System (Invitrogen), following the manufacturer's instructions. The target sequence used to silence LacZ was 5′ -AAATCGCTGATTTGTGTAGTC-3′ . Two distinct sequences to silence IL-32 were used; sequence 1 (5′ -AGAGGGCTACCTGGAGACAGT-3′ ) and sequence 2 (5′ -GAGACAGTGGCGGCTTATTAT-3′ ). Viral concentrations were determined by in vitro transduction in HT1080 cells and using blasticidin selection.
Transduction of lentivirus. HS5 cells were transduced with lentivirus-mediated miRNA targeting LacZ (named miControl) or lentivirus-mediated miRNA targeting IL-32; miIL32#1 for sequence 1 and miIL32#2 for sequence 2. Briefly, HS5 cell lines were seeded onto six-well plates at 5 × 10 4 cells/well, grown overnight, and transduced with lentiviral vectors at a multiplicity of infection equal to 1 in a minimal volume of medium containing 6 mg/mL of polybrene (Sigma-Aldrich, St. Louis, MO, USA). The transduced cells were selected for 15 days using blasticidin (10 μ g/mL) before functional analyses.
Western blotting. Western blot analysis was performed as described previously 82 . Anti-IL-32 (sc-134446) and actin (sc-1616) antibodies were obtained from Santa Cruz Biotechnology. Anti-phospho-SAPK/JNK (Thr183/Tyr185; #9251), SAPK/JNK (9252), phospho-p38 MAPK (Thr180/Tyr182; 9211), p38 MAPK (8690), phospho-NF-κ B p65 (Ser468; 3039), NF-κ B p65 (4764), phospho-IKKα /β (Ser176/180; 2697), IKKα (2682) and IKKβ (8943) were obtained from Cell Signaling. Quantification of band intensity was performed by UN-SCAN-IT (Silk Scientific, Orem, UT, USA).
Cell viability of HS5 cells. Cell viability was measured by methylthiazoletetrazolium (MTT) assay. After 16 h of serum starvation, cells were stimulated to reenter the cell cycle and to proliferate using DMEM supplemented with 10% FBS. Serum starvation was not toxic to the cells (evaluated by Trypan blue; data not shown). A total of 9 × 10 3 cells per well were plated in 96-well plates in DMEM 10% FBS in the absence or presence of proinflammatory cytokines (10 ng/mL TNF-α and 10 ng/mL IFN-γ ) for 48 h. In brief, 10 μ L of a 5 mg/mL solution of MTT was added to the wells and incubated at 37 °C for 4 h. The reaction was stopped using 100 μ L of 0.1 N HCl in anhydrous isopropanol. Cell viability was evaluated by measuring the absorbance at 570 nm, using an automated plate reader. All conditions were tested in six replicates.
Cell proliferation by Ki-67 staining. After 16 h of serum starvation, cells were stimulated to reenter the cell cycle and to proliferate using DMEM supplemented with 10% FBS, exposed or not to the proinflammatory environment (10 ng/mL TNF-α and 10 ng/mL IFN-γ ). Ki-67 staining was performed following the manufacturer's instructions (Ki-67 APC clone B56; Becton-Dickinson) and the mean fluorescence intensity (M.F.I.) was obtained by flow cytometry (FACSCalibur, Becton Dickinson). An IgG isotype was used as a negative control for each condition. Ten thousand events were acquired for each sample.
Chemotaxis assay. We performed a coculture of miControl or miIL32 HS5 cells and PBMC using a transwell culture system (8 μ M-pore size membrane, Corning, NY, USA). HS5 cells were seeded in the lower chamber in DMEM/0.3% BSA exposed or not to an inflammatory environment (10 ng/mL TNF-α and 10 ng/mL IFN-γ ). After 24 h, PBMC were seeded in the upper chamber (10 5 cells/well). After 5 h, migrated cells were analyzed; cells from the lower chamber were trypsinized, stained with anti-CD45, anti-CD14, anti-CD4, and anti-CD8 and analyzed by flow cytometry. Results were calculated as the percentage of the 100% migration value (input).
Chemosensitivity assay to AraC. U937 cells were cocultured with miControl or miIL32 HS5 cells in two distinct conditions: direct contact or noncontact (using a 0.4 μ m porous transwell insert that allows passage of soluble growth factors). Cells were allowed to grow for 96 h and AraC (1 μ M) with or without TNF-α (10 ng/mL) was added in the last 18 h of experiment. Cells were collected and submitted to Annexin-V-APC/PI double staining for flow cytometry. U937 cells were distinguished from miControl or miIL32 HS5 cells by a gate in GFP-positive cells. The analysis was performed using FACSDiva software (version 4.0.1, Becton-Dickinson).
Bio-Plex human cytokine quantification assay. Culture supernatants from miControl and miIL32 HS5 cells, exposed or not to the proinflammatory environment (10 ng/mL TNF-α and 10 ng/mL IFN-γ ), were assayed for several cytokines, chemokines and growth factors using a Bio-Plex human cytokine 27-plex and 21-plex panel assay (Bio-Rad, Hercules, CA, USA). Samples were tested according to the manufacturer's instruction. Data were collected and analyzed using a Bio-Rad BioPlex 200 instrument equipped with Bio-Plex Manager software version 6.0 (Bio-Rad Laboratory, Hercules, CA, USA).
Statistical analysis. Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). For comparisons, Mann-Whitney or Student t tests were used for measured factors with 2 levels; ANOVA followed by post-hoc Bonferroni was used for measured factors with 3 or more levels. A p < 0.05 was considered as statistically significant.
